Binding and cytotoxicity of HPMA copolymer conjugates to lymphocytes mediated by receptor-binding epitopes

Pharmaceutical Research

Volumn 20, Issue 3, 2003, Pages 360-367

  Tang, Aijun ^a   Kopečková, Pavla ^a,b   Kopeček, Jindřich ^a,b  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

Binding affinity; CD21 receptor; Cytotoxicity; Epitope; HPMA copolymer conjugates; Lymphocytes

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; DOXORUBICIN; EPITOPE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PEPTIDE;

ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL ASSAY; CELL LINE; CONJUGATE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOMA CELL; PRIORITY JOURNAL; RAJI CELL; RECEPTOR BINDING; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; CELLS, CULTURED; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; EPITOPES; FLUORESCEIN-5-ISOTHIOCYANATE; HUMANS; KINETICS; POLYMERS; POLYMETHACRYLIC ACIDS; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 0037334066     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022639701388     Document Type: Article

References (30)

1. The Leukemia & Lymphoma Society. http://www.leukemia-lymphoma.org.
2. D. Putnam and J. Kopeček. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:55-123 (1995).
3. J. Kopeček, P. Kopečková, T. Minko, and Z. Lu. HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. Eur. J. Pharm. Biopharm. 50:61-81 (2000).
4. H. Maeda, L. W. Seymour, and Y. Miyamoto. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug. Chem. 3:351-362 (1992).
5. T. Minko, P. Kopečková, V. Pozharov, and J. Kopeček. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 54:223-233 (1998).
6. T. Minko, P. Kopečková, and J. Kopeček. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res. 16:986-996 (1999).
7. T. Minko, P. Kopečkowá. and J. Kopeček. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer 86:108-117 (2000).
8. R. C. Rath, P. Kopečková, and J. Kopeček. Biorecognition of sugar containing N-(2-hydroxypropyl)methacrylamide copolymers by immobilized lectin. Macromol. Chem. Phys. 198:1165-1180 (1997).
9. B. Říhová, P. Kopečková, J. Strohalm, P. Rossmann V. Větvička, and J. Kopeček. Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46:100-114 (1988).
10. Z. R. Lu, P. Kopečková, and J. Kopeček. Polymerizable Fab' antibody fragments for targeting of anticancer drugs. Nat. Biotechnol. 17:1101-1104 (1999).
11. T. F. Tedder, L. T. Clement, and M. D. Cooper. Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J. Immunol. 133:678-683 (1984).
12. E. Fischer, C. Delibrias, and M. D. Kazatchkine. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J. Immunol. 146:865-869 (1991).
13. R. Rask, J. M. Rasmussen, H. V. Hansen, P. Bysted, and S.-E. Svehag. Complement C3d,g/Epstein-Barr virus receptor density on human B-lymphocytes estimated by immunoenzymatic assay and immunocytochemistry. J. Clin. Lab. Immunol. 25:153-156 (1988).
14. + (cytotoxic/suppressor) T lymphocytes. J. Gen. Virol. 71:379-386 (1990).
15. G. R. Nemerow, C. Mold, V. K. Schwend, V. Tollefson, and N. R. Cooper. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 61:1416-1420 (1987).
16. G. R. Nemerow, R. A. Houghten, M. D. Moore, and N. R. Cooper. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56:369-377 (1989).
17. V. Omelyanenko, P. Kopečková, R. K. Prakash, C. D. Ebert, and J. Kopeček. Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes. Pharm. Res. 16:1010-1019 (1999).
18. A. Tang. and J. Kopeček. Presentation of epitopes on genetically engineered peptides and selection of lymphoma-targeting moieties based on epitope biorecognition. Biomacromolecules 3:421-431 (2002).
19. J. Kopeček and H. Bažilová. Poly[N-(2-hydroxypropyl)methacrylamide]-I. Radical polymerization and copolymerization. Eur. Polym. J. 9:7-14 (1973).
20. P. Rejmanová, J. Labský, and J. Kopeček. Aminolyses of monomeric and polymeric p-nitrophenol esters of methacryloylated amino acids. Makromol. Chem. 178:2159-2168 (1977).
21. K. Ulbrich. V. Šubr, J. Strohalm, D. Plocová, M. Jelínková, and B. Říhová. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterisation. J. Control. Release 64:63-79 (2000).
22. V. Omelyanenko, P. Kopečková, C. Gentry, and J. Kopeček. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Release 53:25-37 (1998).
23. M. B. Hansen, S. E. Nielsen, and K. Berg. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 119:203-210 (1989).
24. P. Rejmanová, J. Kopeček, J. Pohl, M. Baudyš, and V. Kostka. Polymers containing enzymatically degradble bonds 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184:2009-2020 (1983).
25. J. A. Hedrick, D. Watry, C. Speiser, P. O'Donnell, J. D. Lambris, and C. D. Tsoukas. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2. Eur. J. Immunol. 22:1123-1131 (1992).
26. J. A. Hedrick, Z. Lao, S. G. Lipps, Y. Wang, S. C. Todd, J. D. Lambris, and C. D. Tsoukas. Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells. J. Immunol. 153:4418-4426 (1994).
27. M. D. Moore, R. G. DiScipio, N. R. Cooper, and G. R. Nemerow. Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). J. Biol. Chem. 264:20576-20582 (1989).
28. C. A. Lowell, L. B. Klickstein, R. H. Carter, J. A. Mitchell D. T. Fearon, and J. M. Ahearn. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J. Exp. Med. 170:1931-1946 (1989).
29. S. E. Henson, D. Smith, S. A. Boackle, V. M. Holers, and D. R. Karp. Generation of recombinant human C3dg tetramers for the analysis of CD21 binding and function. J. Immunol. Methods 258:97-109 (2001).
30. M. W. Hess, M. G. Schwendinger, E. L. Eskelinen, K. Pfaller, M. Pavelka, M. P. Dierich, and W. M. Prodinger. Tracing uptake of C3dg-conjugated antigen into B cells via complement receptor type 2 (CR2, CD21). Blood 95:2617-2623 (2000).